Mei Sheng Duh, ScD, MPH

Analysis Group, Inc., Boston, MA

Poster(s):

• (070) NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (108) Impact of Treatment of COVID-19 with Sotrovimab on Post-Acute COVID-19 Syndrome: An Analysis of National COVID Cohort Collaborative (N3C) Data
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (342) Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST